Prognostic value of impaired hepato-renal function and liver fibrosis in patients admitted for acute heart failure.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
04 2021
Historique:
revised: 04 12 2020
received: 14 08 2020
accepted: 15 12 2020
pubmed: 21 1 2021
medline: 2 7 2021
entrez: 20 1 2021
Statut: ppublish

Résumé

Cardiohepatic interactions have been a focus of attention in heart failure (HF). The model for end-stage liver disease excluding international normalized ratio (MELD-XI) score has been shown to be useful for predicting poor outcomes in patients with acute decompensated HF (ADHF). Furthermore, the fibrosis-4 (FIB-4) index, a simple marker to assess liver fibrosis, predicts adverse prognoses in patients with HF as well. However, there is little information available on the prognostic significance of the combination of the MELD-XI score and FIB-4 index in patients with ADHF and its association with left ventricular ejection fraction (LVEF) subgroup. We prospectively studied 466 consecutive patients who were admitted for ADHF [HF with reduced LVEF (LVEF < 40%): n = 164, HF with mid-range LVEF (40% ≤ LVEF < 50%): n = 104, and HF with preserved LVEF (LVEF ≥ 50%): n = 198]. We calculated the MELD-XI score and FIB-4 indices at discharge. The primary endpoint was all-cause death (ACD). During the mean follow-up period of 2.8 years, 143 patients had ACD. In the multivariate Cox analysis, the MELD-XI score and FIB-4 index were independently associated with ACD. Patients were stratified into the following three groups according to the median value of MELD-XI score (=11) and FIB-4 index (=2.13): Group 1 had both a low MELD-XI score and a low FIB-4 index; Group 2 had either a high MELD-XI score (MELD-XI score ≥11) or a high FIB-4 index (FIB-4 index ≥2.13); and Group 3 had both a high MELD-XI score and a high FIB-4 index. Kaplan-Meier analysis revealed that Group 2 and Group 3 had a significantly greater risk of ACD than Group 1 [Group 2 vs. Group 1: adjusted hazard ratio, 2.48 (95% confidence interval: 1.75-3.53), P < 0.0001; Group 3 vs. Group 1: adjusted hazard ratio, 7.03 (95% confidence interval: 3.95-13.7), P < 0.0001]. In addition, the patients with both a higher MELD-XI score and FIB-4 index showed a significantly higher risk of ACD also in the patients with HF with reduced LVEF, HF with mid-range LVEF, and HF with preserved LVEF (all P < 0.0001). The combination of MELD-XI score and FIB-4 index may be useful for stratifying patients at risk for ACD in patients with ADHF, irrespective of LVEF.

Identifiants

pubmed: 33472273
doi: 10.1002/ehf2.13195
pmc: PMC8006618
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1274-1283

Informations de copyright

© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Heart Vessels. 2018 Jul;33(7):733-739
pubmed: 29288403
Hepatology. 2001 Feb;33(2):464-70
pubmed: 11172350
Clin Gastroenterol Hepatol. 2009 Oct;7(10):1104-12
pubmed: 19523535
Eur J Heart Fail. 2012 Mar;14(3):302-11
pubmed: 22357577
Int J Cardiol. 2016 Nov 15;223:1035-1044
pubmed: 27592046
ESC Heart Fail. 2021 Apr;8(2):1274-1283
pubmed: 33472273
J Am Coll Cardiol. 2013 Jun 18;61(24):2397-2405
pubmed: 23603231
Liver Transpl. 2007 Jan;13(1):30-7
pubmed: 17154400
Am J Clin Nutr. 2019 Aug 1;110(2):330-339
pubmed: 31161211
ESC Heart Fail. 2019 Dec;6(6):1188-1198
pubmed: 31568696
Eur J Heart Fail. 2012 Jun;14(6):621-7
pubmed: 22523374
Eur J Heart Fail. 2016 Dec;18(12):1518-1521
pubmed: 27709804
Circ J. 2018 Mar 23;82(4):1041-1050
pubmed: 29467355
Open Heart. 2017 Apr 28;4(1):e000598
pubmed: 28674631
PLoS One. 2019 Nov 19;14(11):e0225403
pubmed: 31743362
Int J Cardiol Heart Vasc. 2018 Jul 23;20:32-37
pubmed: 30094333
Am J Cardiol. 2016 Jun 15;117(12):1947-52
pubmed: 27237625
Am J Physiol. 1969 Jun;216(6):1441-52
pubmed: 5786730
Int J Angiol. 2011 Sep;20(3):135-42
pubmed: 22942628
Int Heart J. 2019 Sep 27;60(5):1147-1153
pubmed: 31484872
ESC Heart Fail. 2018 Apr;5(2):262-270
pubmed: 28967709
Eur J Clin Invest. 2012 Feb;42(2):153-63
pubmed: 21806605
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Eur J Heart Fail. 2016 Jul;18(7):830-9
pubmed: 27170455
PLoS One. 2014 Jun 23;9(6):e100618
pubmed: 24955578
Am J Gastroenterol. 2017 May;112(5):740-751
pubmed: 27725647
Eur J Heart Fail. 2016 Apr;18(4):424-32
pubmed: 26707029

Auteurs

Masatsugu Kawahira (M)

Division of Cardiology, Osaka General Medical Center, 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558, Japan.

Shunsuke Tamaki (S)

Division of Cardiology, Osaka General Medical Center, 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558, Japan.

Takahisa Yamada (T)

Division of Cardiology, Osaka General Medical Center, 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558, Japan.

Tetsuya Watanabe (T)

Division of Cardiology, Osaka General Medical Center, 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558, Japan.

Takashi Morita (T)

Division of Cardiology, Osaka General Medical Center, 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558, Japan.

Yoshio Furukawa (Y)

Division of Cardiology, Osaka General Medical Center, 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558, Japan.

Masato Kawasaki (M)

Division of Cardiology, Osaka General Medical Center, 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558, Japan.

Atsushi Kikuchi (A)

Division of Cardiology, Osaka General Medical Center, 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558, Japan.

Tsutomu Kawai (T)

Division of Cardiology, Osaka General Medical Center, 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558, Japan.

Masahiro Seo (M)

Division of Cardiology, Osaka General Medical Center, 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558, Japan.

Jun Nakamura (J)

Division of Cardiology, Osaka General Medical Center, 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558, Japan.

Kiyomi Kayama (K)

Division of Cardiology, Osaka General Medical Center, 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558, Japan.

Takanari Kimura (T)

Division of Cardiology, Osaka General Medical Center, 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558, Japan.

Kunpei Ueda (K)

Division of Cardiology, Osaka General Medical Center, 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558, Japan.

Daisuke Sakamoto (D)

Division of Cardiology, Osaka General Medical Center, 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558, Japan.

Takehiro Kogame (T)

Division of Cardiology, Osaka General Medical Center, 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558, Japan.

Shota Ito (S)

Division of Cardiology, Osaka General Medical Center, 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558, Japan.

Yongchol Chang (Y)

Division of Cardiology, Osaka General Medical Center, 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558, Japan.

Masatake Fukunami (M)

Division of Cardiology, Osaka General Medical Center, 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka, 558-8558, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH